Hematological Oncology Models

Hematology Oncology, or “liquid” tumors consist of a wide range of different cancer types such as leukemias and lymphomas. Historically, methods for modeling hematology oncology malignancies have lagged behind that of solid tumors, forcing drug development scientists to rely on models such as clonally expanded cell lines that do not accurately recapitulate the heterogeneity of the patient disease.  

The hematological PDX model platform from Champions Oncology offers an advancement in studying these cancers and their potential treatments by utilizing primary patient samples that have not been passaged in vivo or in vitro.

Champions Oncology offers a series of in vivo and ex vivo platforms for testing leukemias, including:

  • Acute Myeloid Leukemia (AML)
  • B-Cell Acute Lymphoblastic Leukemia (B-ALL)
  • Non-Hodgkin’s Lymphomas
    • Diffuse Large B-Cell Lymphoma (DLBCL)
    • Mantle Cell Lymphoma (MCL)
AML Modeling Graphic